For the Inventor, By the Inventor

Enter assignee name

Vancouver, Canada

Zymeworks Bc Inc.

USPTO Granted Patents = 18

CIPO Patents = 2

EPO Patents = 6

Trademarks = 8

Forward Citations = 0

Loading Chart...

Loading Chart...

56 inventors (with patents filed for the assignee):

Mario Sanches (6 out of 18 patents)

Dunja Urosev (6 out of 12 patents)

James R Rich (6 out of 16 patents)

4. Nina E Weisser (5 out of 8 patents)

5. Surjit Bhimarao Dixit (5 out of 5 patents)

6. Stuart Daniel Barnscher (4 out of 11 patents)

7. Thomas Spreter Von Kreudenstein (4 out of 18 patents)

8. Tom Han Hsiao Hsieh (4 out of 13 patents)

9. Geoffrey C Winters (4 out of 14 patents)

10. Alexander Laurence Mandel (4 out of 12 patents)

11. Gordon Yiu Kon Ng (3 out of 15 patents)

12. Grant Raymond Wickman (3 out of 8 patents)

13. Adam Louis Corper (3 out of 9 patents)

14. Stacey A L Tom-Yew (3 out of 10 patents)

15. Eric Escobar-Cabrera (3 out of 14 patents)

18 patents: Sort by Forward Citations

1. 12540198 - Antigen-Binding Polypeptide Constructs Comprising Kappa and Lambda Light Chains and Uses Thereof (2026-02-03),

2. 12435157 - Methods of using a bispecific antigen-binding construct targeting HER2 for the treatment of biliary tract cancers (2025-10-07),

3. 12433952 - Antibody-drug conjugates targeting folate receptor alpha and methods of use (2025-10-07),

4. 12357701 - Anti-HER2 biparatopic antibody-drug conjugates and methods of use (2025-07-15),

5. 12304954 - Multivalent and bispecific antibody constructs and methods of use thereof (2025-05-20),

6. 12304945 - Engineered immunoglobulin heavy chain-light chain pairs and uses thereof (2025-05-20),

7. 12303544 - Cytotoxic and anti-mitotic compounds, and methods of using the same (2025-05-20),

8. 12286489 - Modified antigen binding polypeptide constructs and uses thereof (2025-04-29),

9. 12227591 - Antigen-binding constructs targeting HER2 (2025-02-18),

10. 12215166 - Bispecific antigen binding constructs targeting HER2 (2025-02-04),

11. 12157775 - Methods of using bispecific antigen-binding constructs targeting HER2 (2024-12-03),

12. 12152083 - Cytotoxic and anti-mitotic compounds, and methods of using the same (2024-11-26),

13. 12076400 - Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer (2024-09-03),

14. 12060436 - Engineered immunoglobulin heavy chain-light chain pairs and uses thereof (2024-08-13),

15. 11965036 - Bispecific antigen-binding constructs targeting HER2 (2024-04-23),

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. The company's proprietary Azymetric platform enables the design and development of highly customizable antibody-based therapeutics with unique functional attributes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

18 Patents

#47 in

#820 in

#34,099 in the World

Vancouver, Canada

Zymeworks Bc Inc.

Forward Citations = 0

56 inventors:

Mario Sanches (6 out of 18 patents)

Dunja Urosev (6 out of 12 patents)

James R Rich (6 out of 16 patents)

4. Nina E Weisser (5 out of 8 patents)

5. Surjit Bhimarao Dixit (5 out of 5 patents)

Please report any incorrect information to [email protected]

Loading…